***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Malassezia***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 50 | 2.227 | 0.000 | . | 0.0464 | 168.62 | 0.00 | 0.00 | 0.00 | 0.8484 |
|  | [B] 0.10% ZPT | 50 | 2.235 | 0.000 | . | 0.0464 | 171.83 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 50 | 1.098 | -1.133 | <.0001 | 0.0949 | 12.52 | -92.6 | -94.1 | -90.8 | 0.0001 |
|  | [B] 0.10% ZPT | 50 | 0.748 | -1.483 | <.0001 | 0.0949 | 5.59 | -96.7 | -97.4 | -95.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 50 | 2.252 | 0.000 | . | 0.0615 | 178.45 | 0.00 | 0.00 | 0.00 | 0.1924 |
|  | [D] 0.03% ZPT + 0.06% ZC | 50 | 2.202 | 0.000 | . | 0.0615 | 159.28 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 49 | 1.289 | -0.938 | <.0001 | 0.1022 | 19.45 | -88.5 | -90.9 | -85.4 | 0.1396 |
|  | [D] 0.03% ZPT + 0.06% ZC | 49 | 1.173 | -1.054 | <.0001 | 0.1022 | 14.88 | -91.2 | -93.0 | -88.8 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.574 | 0.000 | . | 0.1057 | 0.27 | 0.00 | 0.00 | 0.00 | 0.9208 |
|  | [B] 0.10% ZPT | 86 | -0.580 | 0.000 | . | 0.1057 | 0.26 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -0.746 | -0.162 | 0.0375 | 0.0765 | 0.18 | -31.1 | -42.2 | -17.8 | 0.1173 |
|  | [B] 0.10% ZPT | 85 | -0.860 | -0.276 | 0.0005 | 0.0765 | 0.14 | -47.0 | -55.6 | -36.8 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.598 | 0.000 | . | 0.1064 | 0.25 | 0.00 | 0.00 | 0.00 | 0.2364 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.688 | 0.000 | . | 0.1064 | 0.21 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -0.788 | -0.157 | 0.0787 | 0.0883 | 0.16 | -30.4 | -43.2 | -14.7 | 0.2610 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -0.868 | -0.237 | 0.0087 | 0.0883 | 0.14 | -42.1 | -52.8 | -29.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1raIL1a Ratio***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.214 | 0.000 | . | 0.0681 | 1.64 | 0.00 | 0.00 | 0.00 | 0.7802 |
|  | [B] 0.10% ZPT | 86 | 0.202 | 0.000 | . | 0.0681 | 1.59 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -0.083 | -0.286 | <.0001 | 0.0355 | 0.83 | -48.3 | -52.3 | -43.9 | 0.5241 |
|  | [B] 0.10% ZPT | 85 | -0.109 | -0.312 | <.0001 | 0.0355 | 0.78 | -51.3 | -55.1 | -47.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.200 | 0.000 | . | 0.0791 | 1.58 | 0.00 | 0.00 | 0.00 | 0.3189 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.246 | 0.000 | . | 0.0791 | 1.76 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -0.024 | -0.241 | <.0001 | 0.0430 | 0.95 | -42.7 | -48.1 | -36.7 | 0.9188 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -0.029 | -0.246 | <.0001 | 0.0430 | 0.94 | -43.3 | -48.6 | -37.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.113 | 0.000 | . | 0.0434 | 12.98 | 0.00 | 0.00 | 0.00 | 0.5562 |
|  | [B] 0.10% ZPT | 86 | 1.094 | 0.000 | . | 0.0434 | 12.42 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.815 | -0.288 | <.0001 | 0.0338 | 6.53 | -48.5 | -52.3 | -44.3 | 0.2855 |
|  | [B] 0.10% ZPT | 85 | 0.778 | -0.325 | <.0001 | 0.0338 | 5.99 | -52.7 | -56.3 | -48.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.084 | 0.000 | . | 0.0444 | 12.14 | 0.00 | 0.00 | 0.00 | 0.2957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0444 | 13.12 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.829 | -0.270 | <.0001 | 0.0385 | 6.75 | -46.3 | -50.8 | -41.3 | 0.7446 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.818 | -0.281 | <.0001 | 0.0385 | 6.58 | -47.7 | -52.1 | -42.8 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.900 | 0.000 | . | 0.0373 | 7.94 | 0.00 | 0.00 | 0.00 | 0.7491 |
|  | [B] 0.10% ZPT | 86 | 0.892 | 0.000 | . | 0.0373 | 7.81 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.897 | -0.003 | 0.8982 | 0.0206 | 7.89 | -0.61 | -5.21 | 4.22 | 0.7020 |
|  | [B] 0.10% ZPT | 85 | 0.887 | -0.012 | 0.5459 | 0.0206 | 7.72 | -2.83 | -7.33 | 1.88 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.884 | 0.000 | . | 0.0463 | 7.66 | 0.00 | 0.00 | 0.00 | 0.6611 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.872 | 0.000 | . | 0.0463 | 7.45 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.856 | -0.026 | 0.2883 | 0.0240 | 7.18 | -5.73 | -10.8 | -0.38 | 0.7021 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.844 | -0.037 | 0.1228 | 0.0240 | 6.99 | -8.24 | -13.2 | -3.04 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.308 | 0.000 | . | 0.0238 | 20.31 | 0.00 | 0.00 | 0.00 | 0.7864 |
|  | [B] 0.10% ZPT | 86 | 1.314 | 0.000 | . | 0.0238 | 20.62 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.135 | -0.176 | <.0001 | 0.0206 | 13.64 | -33.3 | -36.3 | -30.0 | 0.2350 |
|  | [B] 0.10% ZPT | 85 | 1.111 | -0.199 | <.0001 | 0.0206 | 12.92 | -36.8 | -39.7 | -33.7 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.321 | 0.000 | . | 0.0264 | 20.96 | 0.00 | 0.00 | 0.00 | 0.3804 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.342 | 0.000 | . | 0.0264 | 21.97 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.134 | -0.194 | <.0001 | 0.0235 | 13.61 | -36.0 | -39.4 | -32.4 | 0.6704 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.143 | -0.185 | <.0001 | 0.0235 | 13.89 | -34.7 | -38.1 | -31.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Cytokine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.988 | 0.000 | . | 0.0294 | 9.72 | 0.00 | 0.00 | 0.00 | 0.9484 |
|  | [B] 0.10% ZPT | 86 | 0.986 | 0.000 | . | 0.0294 | 9.68 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.734 | -0.253 | <.0001 | 0.0300 | 5.42 | -44.1 | -47.9 | -40.1 | 0.1699 |
|  | [B] 0.10% ZPT | 85 | 0.693 | -0.294 | <.0001 | 0.0300 | 4.93 | -49.2 | -52.6 | -45.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.953 | 0.000 | . | 0.0354 | 8.97 | 0.00 | 0.00 | 0.00 | 0.4492 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.974 | 0.000 | . | 0.0354 | 9.42 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.725 | -0.234 | <.0001 | 0.0297 | 5.31 | -41.7 | -45.5 | -37.5 | 0.4744 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.706 | -0.253 | <.0001 | 0.0297 | 5.08 | -44.2 | -47.9 | -40.2 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | 0.9990 |
|  | [B] 0.10% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.390 | -0.336 | 0.0001 | 0.0829 | 2.45 | -53.9 | -61.9 | -44.2 | 0.0562 |
|  | [B] 0.10% ZPT | 85 | 0.250 | -0.476 | <.0001 | 0.0829 | 1.78 | -66.6 | -72.4 | -59.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.724 | 0.000 | . | 0.1120 | 5.29 | 0.00 | 0.00 | 0.00 | 0.3727 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.654 | 0.000 | . | 0.1120 | 4.51 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.351 | -0.346 | 0.0008 | 0.0990 | 2.24 | -54.9 | -64.1 | -43.4 | 0.2576 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.270 | -0.427 | <.0001 | 0.0990 | 1.86 | -62.6 | -70.2 | -53.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 2.101 | 0.000 | . | 0.0591 | 126.17 | 0.00 | 0.00 | 0.00 | 0.6488 |
|  | [B] 0.10% ZPT | 86 | 2.080 | 0.000 | . | 0.0591 | 120.20 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.550 | -0.540 | <.0001 | 0.0522 | 35.46 | -71.2 | -74.4 | -67.5 | 0.1094 |
|  | [B] 0.10% ZPT | 85 | 1.469 | -0.621 | <.0001 | 0.0522 | 29.46 | -76.0 | -78.8 | -73.0 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 2.037 | 0.000 | . | 0.0654 | 108.89 | 0.00 | 0.00 | 0.00 | 0.2398 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 2.092 | 0.000 | . | 0.0654 | 123.56 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.554 | -0.504 | <.0001 | 0.0597 | 35.81 | -68.7 | -72.7 | -64.1 | 0.5728 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.524 | -0.534 | <.0001 | 0.0597 | 33.46 | -70.7 | -74.5 | -66.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.887 | 0.000 | . | 0.0398 | 77.16 | 0.00 | 0.00 | 0.00 | 0.7154 |
|  | [B] 0.10% ZPT | 86 | 1.878 | 0.000 | . | 0.0398 | 75.55 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.631 | -0.256 | <.0001 | 0.0358 | 42.76 | -44.5 | -48.9 | -39.7 | 0.1303 |
|  | [B] 0.10% ZPT | 85 | 1.580 | -0.307 | <.0001 | 0.0358 | 38.02 | -50.6 | -54.5 | -46.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.837 | 0.000 | . | 0.0498 | 68.73 | 0.00 | 0.00 | 0.00 | 0.7537 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.846 | 0.000 | . | 0.0498 | 70.19 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.583 | -0.257 | <.0001 | 0.0392 | 38.32 | -44.7 | -49.5 | -39.5 | 0.3329 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.548 | -0.293 | <.0001 | 0.0392 | 35.29 | -49.1 | -53.5 | -44.3 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.754 | 0.000 | . | 0.0768 | 5.67 | 0.00 | 0.00 | 0.00 | 0.6871 |
|  | [B] 0.10% ZPT | 86 | 0.733 | 0.000 | . | 0.0768 | 5.41 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.163 | -0.572 | <.0001 | 0.0601 | 1.46 | -73.2 | -76.7 | -69.2 | 0.5152 |
|  | [B] 0.10% ZPT | 85 | 0.121 | -0.614 | <.0001 | 0.0601 | 1.32 | -75.7 | -78.8 | -72.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.738 | 0.000 | . | 0.0683 | 5.47 | 0.00 | 0.00 | 0.00 | 0.4100 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.695 | 0.000 | . | 0.0683 | 4.96 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.214 | -0.495 | <.0001 | 0.0654 | 1.64 | -68.0 | -72.5 | -62.8 | 0.3341 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.286 | -0.422 | <.0001 | 0.0654 | 1.93 | -62.2 | -67.5 | -56.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -1.585 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | 0.1971 |
|  | [B] 0.10% ZPT | 86 | -1.540 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -1.626 | -0.062 | 0.1133 | 0.0386 | 0.02 | -13.2 | -20.6 | -5.19 | 0.0779 |
|  | [B] 0.10% ZPT | 85 | -1.711 | -0.147 | 0.0003 | 0.0386 | 0.02 | -28.7 | -34.8 | -22.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -1.513 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | 0.2712 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -1.555 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -1.614 | -0.074 | 0.0718 | 0.0406 | 0.02 | -15.7 | -23.2 | -7.42 | 0.6814 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -1.593 | -0.053 | 0.1945 | 0.0406 | 0.03 | -11.5 | -19.4 | -2.84 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011 Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.722 | 0.000 | . | 0.0712 | 5.27 | 0.00 | 0.00 | 0.00 | 0.8236 |
|  | [B] 0.10% ZPT | 86 | 0.708 | 0.000 | . | 0.0712 | 5.11 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.042 | 0.332 | <.0001 | 0.0480 | 11.02 | 114.9 | 92.41 | 140.0 | 0.3389 |
|  | [B] 0.10% ZPT | 85 | 1.099 | 0.389 | <.0001 | 0.0480 | 12.56 | 145.0 | 119.4 | 173.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.768 | 0.000 | . | 0.0594 | 5.86 | 0.00 | 0.00 | 0.00 | 0.5861 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.736 | 0.000 | . | 0.0594 | 5.44 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.988 | 0.232 | <.0001 | 0.0465 | 9.72 | 70.47 | 53.17 | 89.72 | 0.7386 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.971 | 0.215 | <.0001 | 0.0465 | 9.36 | 64.22 | 47.56 | 82.76 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein SkinMap***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.148 | 0.000 | . | 0.0340 | 14.07 | 0.00 | 0.00 | 0.00 | 0.7299 |
|  | [B] 0.10% ZPT | 86 | 1.138 | 0.000 | . | 0.0340 | 13.73 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.774 | -0.370 | <.0001 | 0.0410 | 5.94 | -57.4 | -61.2 | -53.2 | 0.9183 |
|  | [B] 0.10% ZPT | 85 | 0.769 | -0.375 | <.0001 | 0.0410 | 5.87 | -57.8 | -61.6 | -53.7 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.127 | 0.000 | . | 0.0381 | 13.41 | 0.00 | 0.00 | 0.00 | 0.7466 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0381 | 13.11 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.764 | -0.356 | <.0001 | 0.0454 | 5.81 | -55.9 | -60.3 | -51.1 | 0.6046 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.786 | -0.334 | <.0001 | 0.0454 | 6.12 | -53.6 | -58.2 | -48.5 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.902 | 0.000 | . | 0.0887 | 79.79 | 0.00 | 0.00 | 0.00 | 0.6195 |
|  | [B] 0.10% ZPT | 86 | 1.871 | 0.000 | . | 0.0887 | 74.25 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.938 | -0.941 | <.0001 | 0.0719 | 8.67 | -88.6 | -90.3 | -86.5 | 0.5248 |
|  | [B] 0.10% ZPT | 85 | 0.889 | -0.990 | <.0001 | 0.0719 | 7.74 | -89.8 | -91.3 | -87.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.865 | 0.000 | . | 0.0862 | 73.29 | 0.00 | 0.00 | 0.00 | 0.3990 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.813 | 0.000 | . | 0.0862 | 64.97 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.979 | -0.850 | <.0001 | 0.0817 | 9.52 | -85.9 | -88.3 | -82.9 | 0.2505 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.071 | -0.757 | <.0001 | 0.0817 | 11.79 | -82.5 | -85.5 | -78.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.437 | 0.000 | . | 0.0526 | 0.37 | 0.00 | 0.00 | 0.00 | 0.5035 |
|  | [B] 0.10% ZPT | 86 | -0.402 | 0.000 | . | 0.0526 | 0.40 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -0.856 | -0.436 | <.0001 | 0.0461 | 0.14 | -63.4 | -67.1 | -59.3 | 0.1220 |
|  | [B] 0.10% ZPT | 85 | -0.938 | -0.518 | <.0001 | 0.0461 | 0.12 | -69.7 | -72.7 | -66.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.386 | 0.000 | . | 0.0556 | 0.41 | 0.00 | 0.00 | 0.00 | 0.2586 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.437 | 0.000 | . | 0.0556 | 0.37 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -0.848 | -0.428 | <.0001 | 0.0518 | 0.14 | -62.7 | -66.9 | -58.0 | 0.4691 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -0.809 | -0.388 | <.0001 | 0.0518 | 0.16 | -59.1 | -63.7 | -53.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.870 | 0.000 | . | 0.0590 | 74.18 | 0.00 | 0.00 | 0.00 | 0.6185 |
|  | [B] 0.10% ZPT | 86 | 1.846 | 0.000 | . | 0.0590 | 70.17 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.815 | -0.039 | 0.2748 | 0.0354 | 65.33 | -8.57 | -15.7 | -0.81 | 0.2142 |
|  | [B] 0.10% ZPT | 85 | 1.869 | 0.015 | 0.6790 | 0.0354 | 73.91 | 3.44 | -4.65 | 12.22 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.895 | 0.000 | . | 0.0504 | 78.53 | 0.00 | 0.00 | 0.00 | 0.3748 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.854 | 0.000 | . | 0.0504 | 71.38 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.749 | -0.126 | 0.0012 | 0.0377 | 56.17 | -25.3 | -31.5 | -18.5 | 0.7743 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.760 | -0.116 | 0.0029 | 0.0377 | 57.56 | -23.4 | -29.8 | -16.5 | . |
|  | | | | | | | | | | | |